Press Releases

GI Dynamics Appoints Chief Financial Officer

GI Dynamics Appoints Chief Financial Officer LEXINGTON, Massachusetts & SYDNEY, Australia – 5 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides an innovative treatment for type 2 diabetes and obesity, today announces the appointment of Jim...

read more

Daniel J. Moore Elected Chairman of the Board

Daniel J. Moore Elected Chairman of the Board LEXINGTON, Massachusetts & SYDNEY, Australia – 3 May 2016 AEST – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for type 2 diabetes and obesity, is pleased to announce that the board of...

read more

Appendix 4C Quarterly Report Quarter Ended 31 March 2016

Appendix 4C Quarterly Report Quarter Ended 31 March 2016 LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 29 April 2016 – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, releases its Appendix 4C...

read more

GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer

GI Dynamics Announces the Appointment of Medical Device Industry Veteran Scott Schorer as President & Chief Executive Officer LEXINGTON, Massachusetts & SYDNEY, Australia –23 March 2016 AEDT –The Board of Directors of GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company...

read more

GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier® Therapy (the ENDO Trial)

GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier® Therapy (the ENDO Trial) GI Dynamics to Hold Conference Call and Webcast at 8:30 a.m. AEDT on 16 March 2016 (5:30 p.m. EDT on 15 March 2016) LEXINGTON, Massachusetts & SYDNEY, Australia – 15 March 2016 AEDT...

read more

GI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review

BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...

read more

German Diabetes Society Releases Statement Regarding GI Dynamics’ Termination of U.S. ENDO Trial

Interim analysis of trial data demonstrates statistically significant benefit of EndoBarrier Therapy in reducing blood sugar levels LEXINGTON, Mass. & SYDNEY–29 September 2015–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID), a medical device company that provides innovative...

read more

GI Dynamics, Inc. Announces Corporate Restructuring

LEXINGTON, Massachusetts & SYDNEY, Australia – 21 August 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics), a medical device company that provides innovative treatments for type 2 diabetes and obesity, today announced that it is reducing headcount by approximately 46% as part of its efforts to...

read more

Appendix 4C Quarterly Report Quarter Ended 30 June 2015

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 July 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced its financial results for the quarter ended 30 June...

read more

GI Dynamics Concludes ENDO Trial

A review of interim results to follow   Conference call at 9:00 a.m. AEST on 31 July 2015 (7:00 p.m. EDT on 30 July 2015) LEXINGTON, Massachusetts & SYDNEY, Australia – 30 July 2015 – GI Dynamics, Inc. (ASX: GID) (the Company), a medical device company that provides innovative treatments for...

read more
Page 4 of 18« First...23456...10...Last »